Literature DB >> 8324908

Increased IFN-alpha-induced sensitivity but reduced reactivity of 2',5'-oligoadenylate synthetase (2,5AS) in trisomy 21 blood lymphocytes.

A M Gerdes1, M Hørder, V Bonnevie-Nielsen.   

Abstract

2,5AS is induced by interferon-alpha, -beta (IFN-alpha, -beta) and polymerizes adenosine triphosphate (ATP) into pppA (2'p5'A) oligomers, leading to inhibition of protein synthesis and virus growth. The gene coding for the IFN-alpha, -beta receptor is localized to chromosome 21. In trisomy 21 cells from patients with Down's syndrome a 50% increase in gene dosage is present for the genes on this chromosome. Corresponding increase of gene products has been shown for several of these genes, e.g. the IFN-alpha, -beta receptor molecules. Here, we show a direct proportionality between the number of IFN-alpha, -beta receptors and both the basal activity of 2,5AS and the sensitivity of this enzyme for IFN-alpha, -beta. The relative increase of 2,5AS activity (the reactivity) becomes reduced consistent with the increased basal 2,5AS activity in trisomy 21 cells compared with control cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324908      PMCID: PMC1554756          DOI: 10.1111/j.1365-2249.1993.tb06502.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Chromosome-21-dosage effect on inducibility of anti-viral gene(s).

Authors:  U H Tan
Journal:  Nature       Date:  1975-01-24       Impact factor: 49.962

2.  Lymphoblastogenesis in Down's syndrome and its inhibition by human interferon.

Authors:  D Gurari-Rotman; M Revel; B Tartakovsky; S Segal; T Hahn; Z Handzel; S Levin
Journal:  FEBS Lett       Date:  1978-10-15       Impact factor: 4.124

3.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

4.  Association of IDDM and attenuated response of 2',5'-oligoadenylate synthetase to yellow fever vaccine.

Authors:  V Bonnevie-Nielsen; M L Larsen; J J Frifelt; B Michelsen; A Lernmark
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

5.  Enhanced sensitivity of trisomy 21 monocytes to the maturation-inhibiting effect ot interferon.

Authors:  L B Epstein; S H Lee; C J Epstein
Journal:  Cell Immunol       Date:  1980-03-01       Impact factor: 4.868

6.  Interferon induction of (2'-5') oligoisoadenylate synthetase in diploid and trisomy 21 human fibroblasts: relation to dosage of the interferon receptor gene (IRFC).

Authors:  J Weil; G Tucker; L B Epstein; C J Epstein
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

7.  Inhibition of protein synthesis by 2'-5' linked adenine oligonucleotides in intact cells.

Authors:  B R Williams; I M Kerr
Journal:  Nature       Date:  1978-11-02       Impact factor: 49.962

8.  Effect of human interferon preparations on lymphoblastogenesis in Down's syndrome.

Authors:  C G Cupples; Y H Tan
Journal:  Nature       Date:  1977-05-12       Impact factor: 49.962

9.  Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state.

Authors:  Y H Tan; E L Schneider; J Tischfield; C J Epstein; F H Ruddle
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

10.  Natural killer cell function in trisomy-21 (Down's syndrome).

Authors:  T Nurmi; K Huttunen; O Lassila; M Henttonen; A Säkkinen; S L Linna; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

View more
  3 in total

Review 1.  The cognitive phenotype of Down syndrome: insights from intracellular network analysis.

Authors:  Avi Ma'ayan; Katheleen Gardiner; Ravi Iyengar
Journal:  NeuroRx       Date:  2006-07

Review 2.  Pathophysiology of celiac disease.

Authors:  Sonia S Kupfer; Bana Jabri
Journal:  Gastrointest Endosc Clin N Am       Date:  2012-08-30

Review 3.  The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.

Authors:  M R Player; P F Torrence
Journal:  Pharmacol Ther       Date:  1998-05       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.